Efficacy of immunotherapy (nivolumab, pembrolizumab and atezolizumab) in patients with non-small cell lung cancer
Latest Information Update: 16 Oct 2019
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 16 Oct 2019 New trial record
- 10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer